Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.

Authors:
Chamseddine S; LaPelusa M; Xiao L; Mohamed YI; Lee SS and 8 more

Journal:
J Hepatocell Carcinoma

Publication Year: 2024

DOI:
10.2147/JHC.S452564

PMCID:
PMC10921889

PMID:
38463542

View on PubMed View on PMC View Publisher
Journal Information

Journal Title: J Hepatocell Carcinoma

Detailed journal information not available.

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure Shadi Chamseddine and Michael LaPelusa are co-first authors for this study. Dr Dan Duda reports grants from BMS, Bayer, Exelixis, Surface Oncology; personal fees from Innocoll, outside the submitted work. The authors report no other conflicts of interest in this work."

Evidence found in paper:

"NCI R01 CA260872, P50 CA217674. DGD’s research is funded through NIH grant nos. R01CA260872, R01CA260857, and R01CA247441 and by Department of Defense PRCRP grants nos. W81XWH-19–1-0284, W81XWH1910482, and W81XWH-21–1-0738."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025